Abstract
Twenty-nine with patients recurrent primary malignant brain tumors were treated with 1-(2-chlorethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (PCNU) at an initial dose of 110 Mg/M2 with subsequent doses determined by the degree of delayed toxicity. The interval between treatments was usually weeks. Eleven of 25 evaluable patients (44%) showed definite improvement and ten(40%) showed disease stability as determined by sequential CT scans and neurologic examination. The estimated median time to tumor progression for all 25 patients treated with PCNU was 28 weeks, 37 weeks for the responding patients but only 20 weeks for patients with stable disease. Toxicity consisted of delayed myelosuppression which was cumulative and occurred mainly with the platelets. Gastrointestinal toxicity occurred in a minority of the patients. PCNU has definite activity in primary malignant brain tumors which appears to be comparable to that reported for BCNU alone, but with less reported gastointestinal side effects. Further clinical trials in patients with primary malignant brain tumors are indicated.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Walker MD, Alexander E Jr, Hunt WE et al.: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 49: 333–343, 1978.
Kramer S: Radiation therapy in the management of malignant gliomas. In: Proc Seventh Natl Cancer Conf., Los Angeles, CA, Sept 27–29, 1972. JB Lippincott Philadelphia, 1973, pp 823–825.
Wilson CB, Gutin P, Boldrey EB, Crafts D, Levin VA, Enot KJ: Single-agent chemotherapy of brain tumors - a five year review. Arch Neurol 33: 739–744, 1976.
Levin VA, Wilson CB: Chemotherapy: agents in current use. Semin Oncol 2:63–67, 1975.
Wilson CB, Boldrey EB, Enot KJ: BCNU in the treatment of brain tumors. Cancer Chemother Rep 54: 273–281, 1970.
Stewart DJ, Benjamin RS, Leavens M et al.: Phase I Study of PCNU. Proc Am Assoc Clinical Res 21: 168, 1980.
Wheeler GP, Bowden BJ, Grimsley JA et al.: Interrelationships of some chemical physicochemical, and biological activities of several 1-(2 halo ethyl)- 1-nitrosoureas. Cancer Res 34: 194–200, 1974.
Levin VA, Kabra PM: Effectiveness of the nitrosoureas as a function of their lipid solubility in the chemotherapy of experimental rat brain tumors. Cancer Chemother Rep 58: 787–792, 1974.
Gehan EA: A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 52:203–223, 1965.
Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481, 1958.
Yung WK, Rankin JK, Shapiro WR: Heterogenous chemosensitivities of human gliomas cell lines by colony forming assay. Proc Am Assoc Clinical Res 22:217, 1981.
Moertel CG, Reitemeier RJ, Hahn RG: Therapy of advanced gastrointestinal cancer with BCNU. Clinical Pharm Therapy 9:652–656, 1968.
Iriarte PV, Hananian J, Cortner JA: Central Nervous System leukemia and solid tumors of childhood-treatment with BCNU. Cancer 19:1187–1191, 1966.
DeVita VT, Carbone PP, Owen AH Jr et al.: Clinical trials with BCNU. Cancer Res 25:1876–1881, 1965.
Levin VA, Hoffman WF, Pischer TL, Seager ML, Boldrey EB, Wilson CB: BCNU-5-fluorouracil combination for recurrent malignant brain tumors. Cancer Treat Rep 62: 2071–2076, 1978.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Feun, L.G., Stewart, D.J., Leavens, M.E. et al. A phase II trial of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (PCNU, NSC 95466) in recurrent malignant brain tumors. J Neuro-Oncol 1, 45–48 (1983). https://doi.org/10.1007/BF00153640
Issue Date:
DOI: https://doi.org/10.1007/BF00153640